Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Rhea-AI Summary

Predictmedix AI (OTC: PMEDF) closed the final tranche of a non-brokered private placement on December 5, 2025, issuing 3,050,000 Units at C$0.05 each for gross proceeds of $152,500, bringing total capital raised across all tranches to $612,650.

Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 for 36 months. Warrants may be accelerated if the CSE volume-weighted average share price equals or exceeds C$0.30 for 10 consecutive trading days after the four-month hold.

All securities are subject to a statutory hold of four months and one day. Management described the raise as selective and strategic, focused on investors who add operational value rather than maximizing capital.

Positive

• Total gross proceeds of $612,650 raised across the Offering
• Final tranche raised $152,500 via 3,050,000 Units
• Warrants exercisable at C$0.15 for 36 months

Negative

• Issued 3,050,000 new Units in final tranche, creating share dilution
• Warrants include acceleration clause if VWAP ≥ C$0.30, altering potential timing of dilution
• All securities subject to statutory hold of 4 months and 1 day, limiting immediate liquidity for investors

News Market Reaction

-12.30%

1 alert

-12.30% News Effect

On the day this news was published, PMEDF declined 12.30%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Units issued (final tranche): 3,050,000 units Unit price: $0.05 per Unit Gross proceeds (tranche): $152,500 +5 more

8 metrics

Units issued (final tranche) 3,050,000 units Final tranche of non-brokered private placement

Unit price $0.05 per Unit Pricing for final tranche units

Gross proceeds (tranche) $152,500 Capital raised in final tranche

Total capital raised $612,650 Aggregate across all tranches of the Offering

Warrant exercise price C$0.15 Exercise price per common share under Warrants

Warrant term 36 months Duration from closing date of the Offering

Acceleration trigger price $0.30 VWAP 10 consecutive trading days after hold period

Statutory hold period Four months and one day Restriction on securities issued in placement

Market Reality Check

Price: $0.0380 Vol: Volume 100 is far below t...

normal vol

$0.0380 Last Close

Volume Volume 100 is far below the 20-day average of 67,170, suggesting limited pre-news trading interest. normal

Technical Price 0.0542 sits above the 0.02 200-day moving average, indicating a pre-news uptrend.

Peers on Argus

While PMEDF showed a -12.3% move pre-news, peers were mixed, with names like KLY...

While PMEDF showed a -12.3% move pre-news, peers were mixed, with names like KLYG and TBRIF up strongly and IRME down, pointing to stock-specific dynamics rather than a unified sector trend.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Financing tranche close	Positive	-12.3%	Closed final tranche of non-brokered private placement, raising <b>$152,500</b>.
Nov 17	Financing tranche close	Positive	+117.4%	Closed first tranche of non-brokered placement, raising <b>$460,150</b> at C$0.05.
Oct 20	Financing announcement	Positive	-6.2%	Announced proposed non-brokered private placement of up to <b>18,000,000</b> units.
Sep 29	Conference participation	Positive	+8.2%	Announced presentation at the <b>25th MK Investment Conference</b> in Munich.
Sep 24	Strategy update	Positive	+21.0%	Unveiled multi-vertical AI health-tech growth strategy across three platforms.

Pattern Detected

News tied to AI strategy and conferences often aligned with positive moves, while private placement announcements have shown mixed reactions, including both strong gains and notable declines.

Recent Company History

Over the last few months, Predictmedix AI issued several updates combining financing and strategic growth. On Sep 24, it outlined a multi-vertical AI health-tech strategy, followed by a conference appearance on Sep 29. A non-brokered private placement was announced on Oct 20, then a first tranche closing on Nov 17, and the final tranche closing on Dec 5, bringing total proceeds to $612,650. Historically, strategy and conference news skewed positive, while private placement items showed more varied price reactions.

Market Pulse Summary

The stock dropped -12.3% in the session following this news. A negative reaction despite management ...

Analysis

The stock dropped -12.3% in the session following this news. A negative reaction despite management framing the raise as strategic fits prior mixed responses to private placements, including a -6.16% move on an earlier financing announcement. Investors may have focused on dilution and warrant overhang even as total proceeds reached $612,650 to support growth plans. Past positive reactions to AI strategy and conference news underline that sentiment has been sensitive to how new capital translates into tangible milestones.

Key Terms

non-brokered private placement, warrant, volume weighted average price, statutory hold period

4 terms

non-brokered private placement financial

"final tranche of its non-brokered private placement (the "Offering")"

A non-brokered private placement is when a company raises money by selling securities (such as shares or bonds) directly to a small group of chosen investors without using a broker or dealer as a middleman. For investors it matters because it can provide faster, lower-cost access to new investment opportunities but may bring higher risk, less liquidity and potential dilution of existing holdings compared with public offerings.

warrant financial

"one half of one common share purchase warrant (each, a "Warrant")"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

volume weighted average price technical

"the volume weighted average price of the Common Shares on the CSE"

The volume weighted average price (VWAP) is a way to measure the average price of a security, such as a stock, over a specific period, taking into account how many units were traded at each price. It’s similar to calculating the average cost of items bought when some are more frequently purchased than others. Investors use VWAP to assess whether a security is being bought or sold at a fair price during trading.

statutory hold period regulatory

"subject to a statutory hold period of four months and one day"

A statutory hold period is a legally required time window during which newly issued securities or shares received by insiders cannot be sold. It matters to investors because it affects when those shares can enter the market, influencing supply, short-term liquidity and potential price pressure—think of it like a temporary “no-sell” tag that prevents an immediate flood of items onto a store shelf after a big restock.

AI-generated analysis. Not financial advice.

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that it has successfully closed the final tranche of its non-brokered private placement (the "Offering").

In this final tranche, the Company issued 3,050,000 units ("Units") at a price of $0.05 per Unit, for gross proceeds of $152,500, bringing the total capital raised across all tranches of the Offering to $612,650.

The Company issued 3,050,000 units ("Units") at a price of $0.05 per Unit, raising $152,500 in this tranche. Each Unit consists of one common share of Predictmedix and one half of one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one half Common Share of the Company at a price of C$0.15 for a period of 36 months following the closing date of the Offering. If, following four months and a day after the Closing Date, the volume weighted average price of the Common Shares on the CSE is equal to or greater than $0.30 for any 10 consecutive trading days, the Corporation may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

"We are pleased to complete this financing with a select group of strategic participants who align closely with our long-term vision," said Dr. Rahul Kushwah, COO of Predictmedix AI. "In order to maintain share-structure integrity and avoid unnecessary dilution for our long-term investors, we opted to accept a reduced amount and take a disciplined, value-focused approach to the raise. Our priority was to welcome investors who bring meaningful strategic contributions through their expertise and networks, rather than simply maximizing capital. With this measured financing now concluded, we are moving ahead with clarity and strong momentum as we continue advancing our initiatives across key markets."

All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day from the date of issuance.

Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Contact
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277051

FAQ

How much did Predictmedix (PMEDF) raise in the final tranche on December 5, 2025?

The final tranche raised $152,500 by issuing 3,050,000 Units at C$0.05 each.

What are the warrant terms for Predictmedix (PMEDF) Units issued in the private placement?

Each half-warrant converts to one full Warrant exercisable at C$0.15 for 36 months from closing.

When can Predictmedix (PMEDF) accelerate Warrant expiry and what is the trigger?

If, after 4 months and 1 day, the CSE VWAP is ≥ C$0.30 for any 10 consecutive trading days, the company may accelerate expiry to 30 days after notice.

What is the total capital raised by Predictmedix (PMEDF) across all tranches of the Offering?

The Offering raised a total of $612,650 across all tranches.

Are the securities issued to investors in the Predictmedix (PMEDF) placement immediately tradable?

No; all securities are subject to a statutory hold period of four months and one day from issuance.